Mikhail Blagosklonny is a scientist and an oncological professor in New York. He specialize in the studies of cancer and aging especially anti-aging. He attended university at the First Pavlov State Medical University, St. Peterburg where he acquired a Ph.D. in cardiology and research medicine. He had also acquired a masters’ degree in internal medicine from the same university. In 2002, he got a job at the New York medical college as an associate professor. He worked as a senior scientist at the Ordway Research Institute until 2009 when he became a professor at the cancer centre. He is also the head of various health science organizations and has lectured in very many prominent cancer institutions.
His main research interest lie in topics such as; cancer and cancer therapies, biogerontology, anti-ageing drugs and any other substances that could protect the normal body cells from aging or damage. In a recent hypothesis, Mikhail Blagosklonny proposes that it might be possible to delay aging with the help of rapamycin, a drug mostly common in cancer medicine. He is a very passionate advocate for the drug and proposes its use to extend the natural life of human beings. He also claimed that Target Of Rapamycin (TOR) is a regulator in the aging mechanisms of most organisms from including humans. Over the last decade, extensive research on the topic shows that TOR determines how growth, development and aging is coordinated by the eukaryotic cells in the body. The cellular system grows in response to the changes in the body’s surrounding environment. This implies that growth factors, availability of food and energy and stress levels are the key in enhancing aging. It is in light of such discoveries that Blagosklonny and other doctors in similar fields seek to find treatment to both, cancer and aging.
Blagosklonny is also an editor of various journals. He is most popular for his input to Oncotarget, a free-access medical journal that is interested in articles in oncology. He also edits other journals such as Aging and Cell Cycle where he is the chief editor. He takes other editorial roles for journals such as Cancer Biology & Therapy and is part of the editorial board for the Cell Death & Differentiation. Visit classroomvoices.org to read more about Mikhail.